StockData
Regeneron Pharmaceuticals, Inc. logo

Regeneron Pharmaceuticals, Inc. (REGN) stock

REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/3010% above fair value
$957.76+5.36 (+0.56%)

Close on Nov 17, 2026Market cap $99.08BP/E 21.2Yield –

Regeneron Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Regeneron Pharmaceuticals's operating cash flow for the twelve months ending Sep 30, 2026 was $4.85B, down 4.4% year over year. For fiscal 2025 it was $4.98B, up 12.6% from the year before. Over ten years it grew 14.1% a year on average. The highest annual figure on record is $7.08B in fiscal 2021.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$4.98B+12.6%
FY2024Dec 31, 2024$4.42B-3.8%
FY2023Dec 31, 2023$4.59B-8.4%
FY2022Dec 31, 2022$5.01B-29.2%
FY2021Dec 31, 2021$7.08B+170.5%
FY2020Dec 31, 2020$2.62B+7.7%
FY2019Dec 31, 2019$2.43B+10.7%
FY2018Dec 31, 2018$2.20B+67.9%
FY2017Dec 31, 2017$1.31B-12.0%
FY2016Dec 31, 2016$1.49B+11.7%
FY2015Dec 31, 2015$1.33B+76.9%
FY2014Dec 31, 2014$752.44M+27.8%
FY2013Dec 31, 2013$588.60M–
FY2012Dec 31, 2012-$74.62M–
FY2011Dec 31, 2011-$141.68M-242.8%
FY2010Dec 31, 2010$99.22M–
FY2009Dec 31, 2009-$69.94M–
FY2008Dec 31, 2008-$89.09M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$1.78B+10.2%
Q2 FY2026Jun 30, 2026$813.00M-29.0%
Q1 FY2026Mar 31, 2026$1.08B+3.2%
Q4 FY2025Dec 31, 2025$1.17B-7.3%
Q3 FY2025Sep 30, 2025$1.62B+25.4%
Q2 FY2025Jun 30, 2025$1.14B+223.3%
Q1 FY2025Mar 31, 2025$1.05B-30.9%
Q4 FY2024Dec 31, 2024$1.26B+15.9%
Q3 FY2024Sep 30, 2024$1.29B+15.9%
Q2 FY2024Jun 30, 2024$354.00M-65.4%
Q1 FY2024Mar 31, 2024$1.51B+10.6%
Q4 FY2023Dec 31, 2023$1.09B-36.6%
Q3 FY2023Sep 30, 2023$1.11B+77.2%
Q2 FY2023Jun 30, 2023$1.02B+81.1%
Q1 FY2023Mar 31, 2023$1.37B-34.9%
Q4 FY2022Dec 31, 2022$1.72B-27.5%
Q3 FY2022Sep 30, 2022$628.90M-81.6%
Q2 FY2022Jun 30, 2022$564.40M-9.9%
Q1 FY2022Mar 31, 2022$2.10B+214.4%
Q4 FY2021Dec 31, 2021$2.37B+92.7%
Q3 FY2021Sep 30, 2021$3.41B–
Q2 FY2021Jun 30, 2021$626.70M-33.6%
Q1 FY2021Mar 31, 2021$668.50M-4.2%
Q4 FY2020Dec 31, 2020$1.23B+56.3%
Q3 FY2020Sep 30, 2020-$254.30M-145.6%
Q2 FY2020Jun 30, 2020$943.40M+401.0%
Q1 FY2020Mar 31, 2020$698.00M-22.2%
Q4 FY2019Dec 31, 2019$787.40M+8.0%
Q3 FY2019Sep 30, 2019$557.30M+23.1%
Q2 FY2019Jun 30, 2019$188.30M-52.3%
Q1 FY2019Mar 31, 2019$897.00M+45.0%
Q4 FY2018Dec 31, 2018$728.80M+28.6%
Q3 FY2018Sep 30, 2018$452.90M+9.2%
Q2 FY2018Jun 30, 2018$394.60M–
Q1 FY2018Mar 31, 2018$618.80M+73.9%
Q4 FY2017Dec 31, 2017$566.94M+45.2%
Q3 FY2017Sep 30, 2017$414.83M–
Q2 FY2017Jun 30, 2017-$30.57M–
Q1 FY2017Mar 31, 2017$355.90M–
Q4 FY2016Dec 31, 2016$390.38M–

More Regeneron Pharmaceuticals figures

See a number that looks wrong?